Key result
Administration of Atorvastatin plus Melatonin decreased fluorescein leakage, MDA, and ROS levels, and prevented retinal vascular congestion compared to diabetic and monotherapy groups in rats.
Why the study?
The study was designed to evaluate the effects of atorvastatin plus melatonin on streptozocin-induced diabetic retinopathy in rats.
Does the combination of melatonin and atorvastatin improve retinopathy in streptozocin-induced diabetic rats?
RCT (n=40)
randomly assigned
Does the combination of melatonin and atorvastatin improve retinopathy in streptozocin-induced diabetic rats?
The combination of melatonin and atorvastatin reduces oxidative stress and prevents retinal vascular congestion in a rat model of diabetic retinopathy.
Supports exploration of atorvastatin-melatonin combination in diabetic retinopathy models; leaves open translation to human therapy.
Objective: The present study was designed to evaluate the effects of Atorvastatin (ATO) plus Melatonin (MEL) on streptozocin-induced Diabetic Retinopathy (DR) in rats. Methods: Diabetes was induced in Wistar rats with an intraperitoneal injection of streptozocin (50 mg/kg). Animals were randomly assigned to one of the following groups (8 rats/group): Control group, Diabetic group, Diabetic + MEL group (20 mg/kg/day), Diabetic + ATO group (10 mg/kg/day), Diabetic + MEL + ATO group (as above). Treatments were started one week after induction of diabetes and continued for 7 weeks. At the end of the experiment, angiography was performed and the rats were killed and retinas were harvested for pathological and molecular examinations. Results: Administration of MEL reduced the fluorescein leakage, MDA and ROS levels compared to diabetic group. Treatment with ATO only reduced ROS levels compared to diabetic group. In addition, administration of ATO plus MEL decreased these indices compared to the diabetic and ATO groups. Histologically, retinal vascular congestion was not observed in the combined ATO and MEL group as compared to the diabetic, ATO, and MEL groups. Conclusion: These data provide evidence for the therapeutic value of MEL in combination with ATO in clinical practice for prevention of DR.
No takes yet. Share an insight, caveat, or question.
Shahriari et al. (2019) conducted an RCT in streptozocin-induced Diabetic Retinopathy (n=40). Atorvastatin plus Melatonin vs. Diabetic control, Melatonin alone, and Atorvastatin alone was evaluated on fluorescein leakage, MDA and ROS levels, and retinal vascular congestion. Administration of Atorvastatin plus Melatonin decreased fluorescein leakage, MDA, and ROS levels, and prevented retinal vascular congestion compared to diabetic and monotherapy groups in rats.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: